Reaction
Retroperitoneal Lymphadenopathy reporting signals
As of the last recalculation, Retroperitoneal Lymphadenopathy appears in 520 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is POLATUZUMAB VEDOTIN (PRR 85.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Polatuzumab Vedotin | 20 | 85.3 | 85.4 |
| Bicalutamide | 24 | 66.0 | 66.1 |
| Regorafenib | 11 | 38.7 | 38.8 |
| Obinutuzumab | 15 | 37.6 | 37.6 |
| Bendamustine Hcl | 13 | 34.4 | 34.4 |
| Sirolimus | 9 | 27.2 | 27.2 |
| Abiraterone | 9 | 26.9 | 26.9 |
| Ado-Trastuzumab Emtansine | 5 | 24.0 | 24.0 |
| Bleomycin Sulfate | 6 | 23.5 | 23.5 |
| Doxorubicin Hydrochloride | 16 | 20.2 | 20.2 |
| Sorafenib | 10 | 19.6 | 19.6 |
| Abiraterone Acetate | 16 | 16.0 | 16.0 |
| Oxaliplatin | 28 | 15.9 | 15.9 |
| Lapatinib | 6 | 15.6 | 15.7 |
| Docetaxel Anhydrous | 23 | 14.2 | 14.3 |
| Docetaxel | 23 | 14.2 | 14.3 |
| Enzalutamide | 20 | 14.1 | 14.1 |
| Atezolizumab | 13 | 13.7 | 13.7 |
| Encorafenib | 3 | 12.2 | 12.2 |